CS-5d Bcr-Abl and Btk small molecule kinase inhibitors

This compound inhibits in nanomolar scale for Bcr-Abl (40 nM) and sub-micromolar scale for Btk kinases (0,58 M), both are related to the genesis and progression of myeloid and lymphoid leukaemia, respectively

Contributors

Inventor Institute
Cristian Salas Pontificia Universidad Catolica de Chile
Cat. #: 160517
Tool sub type: Inhibitor
Research Fields: Cancer
Purpose: Inhibitor
Product description: This compound inhibits in nanomolar scale for Bcr-Abl (40 nM) and sub-micromolar scale for Btk kinases (0,58 <U+00B5>M), both are related to the genesis and progression of myeloid and lymphoid leukaemia, respectively
Molecular weight: 490.5509
Primary target: Bcr-Abl and Btk kinases
Storage conditions: Away from UV light
Shipping conditions: Dry Ice
Solubility: DMSO
References:

Bertrand et al. 2020. Bioorg Chem. 94:103361. PMID: 31699386.

Images

View Gallery
1. CS-5d (9-(Cyclopropylmethyl)-N6-(3;4-difluorophenyl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-9H-purine-2;6-diamine) 2. CS-5c (9-(Cyclopropylmethyl)-N6-(3-fluorophenyl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-9H-purine-2;6-diamine)

Related Tools for Small molecules

Cat. # Tool Name
151831 Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound) Key Info View Tool
151832 LIMK inhibitor CRT0105950 Small Molecule (Tool Compound) Key Info View Tool
151879 AKR1C3 inhibitor CRT0083914 Small Molecule (Tool Compound) Key Info View Tool
152544 Protein Kinase D inhibitor CRT5 (CRT0066051) Small Molecule (Tool Compound) Key Info View Tool
152789 Glucose-6-phosphate Dehydrogenase inhibitor G6PD Small Molecule (Collaborative Toolkit) Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.